Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 8/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.49 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.43 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.43 |
| ▸ | GPR34 | Q9UPC5 | 4/20 | 0.42 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 2/20 | 0.41 |
| ▸ | ACE | P12821 | 2/20 | 0.41 |
| ▸ | CPA1 | P15085 | 2/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5927218 | 0.99 | ITGB3 (0.47) | ITGB3ITGA2BKIFC1ITGB1ITGA4 | |
| SCHEMBL5926927 | 0.93 | HDAC1 (0.48) | — | |
| SCHEMBL5926496 | 0.92 | ITGB3 (0.44) | ITGB3ITGA2BKIFC1ITGB1ITGA4 | |
| SCHEMBL5927496 | 0.92 | ITGB3 (0.44) | ITGB3ITGA2BKIFC1ITGB1ITGA4 | |
| SCHEMBL5926426 | 0.92 | HDAC1 (0.46) | — | |
| SCHEMBL5926565 | 0.91 | KIFC1 (0.44) | ITGB3ITGA2BKIFC1ITGB1ITGA4 | |
| SCHEMBL3995844 | 0.88 | KIFC1 (0.45) | ITGB3ITGA2BKIFC1ITGB1ITGA4 | |
| SCHEMBL3994279 | 0.86 | PTPN11 (0.51) | ITGB3ITGA2BKIFC1ITGB1ITGA4 | |
| SCHEMBL4829715 | 0.86 | PTPN11 (0.51) | ITGB3ITGA2BKIFC1ITGB1ITGA4 | |
| SCHEMBL5926489 | 0.85 | CTSA (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | ITGB3 71/4885ITGA2B 93/4885KIFC1 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.